Opinion

Video

Exploring the Role of BTKi-Based Combination Therapies for Front-line Management of CLL

Author(s):

Catherine C. Coombs, MD,Brian T. Hill, MD, PhD

Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
David C. Fisher, MD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
David C. Fisher, MD, of Dana-Farber Cancer Institute
October 21st 2024

New Data Shed Light on the Efficacy of BTK Inhibitors in the CLL Treatment Paradigm

Aaron T. Gerds, MD, MS, assistant professor, Department of Medicine, School of Medicine, member, Developmental Therapeutics Program, Case Comprehensive Cancer Center, physician,Department of Hematology and Medical Oncology, Cleveland Clinic; James K. McCloskey, MD, interim chief, Division of Leukemia, Hackensack John Theurer Cancer Center
October 14th 2024

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

Danielle M. Brander, MD
October 16th 2024

Venetoclax/Rituximab Retreatment Produces Durable Responses in CLL

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Jeanette Lundin, MD, PhD, Karolinska University Hospital
October 8th 2024

Response-Based Intermittent Ibrutinib Dosing Shows Safety, Feasibility in CLL

Joshua Linscott, MD, PhD
September 13th 2024

utDNA Could Provide Noninvasive Tool for MRD Detection Prior to Repeat TURBT in High-Risk NMIBC